Osteoclasts, as the only cells capable of resorbing bone, play a significant role in all processes that take place at the level of bone tissue and are involved in the development of the skeleton, maintenance of its integrity, repair, and regeneration of bones. Therefore, it is not surprising that even small deviations from their normal functioning result in diseases that not only affect skeletal system but also the entire organism. There are a number of rare genetic bone diseases associated with mutations in osteoclast genes that govern their differentiation and function. Specifically, they are known as osteoclast-related diseases, and their main hallmark is either decreased or increased bone resorption. To understand the impact of osteoclast gene mutations on the course of these diseases, it is also necessary to know the cellular and molecular mechanisms underlying osteoclast development and function. Moreover, identification of specific gene mutations as potential therapeutic targets would be an important step in creating personalized gene therapies in the future.
AkerM, RouvinskiA, HashaviaS, et al.An SNX10 mutation causes malignant osteopetrosis of infancy. J Med Genet, 2012; 49(4):221–226; doi: 10.1136/jmedgenet-2011-100520
2.
AndersonDM, MaraskovskyE, BillingsleyWL, et al.A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997; 390(6656):175–179; doi: 10.1038/36593
3.
ArmstrongAP, TometskoME, GlaccumM, et al.A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem, 2002; 277(46):44347–44356; doi: 10.1074/jbc.M202009200
4.
AsagiriM, TakayanagiH. The molecular understanding of osteoclast differentiation. Bone, 2007; 40(2):251–264; doi: 10.1016/j.bone.2006.09.023
5.
BalemansW, Van WesenbeeckL, Van HulW. A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int, 2005; 77(5):263–274; doi: 10.1007/s00223-005-0027-6
6.
BarrowAD, RaynalN, AndersenTL, et al.OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest, 2011; 121(9):3505–3516; doi: 10.1172/JCI45913
7.
Bar-ShavitZ. The osteoclast: A multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. J Cell Biochem, 2007; 102(5):1130–1139; doi: 10.1002/jcb.21553
8.
BénichouOD, LaredoJD, de VernejoulMC. Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): Clinical and radiological manifestations in 42 patients. Bone, 2000; 26(1):87–93; doi: 10.1016/s8756-3282(99)00244-6
9.
BhatS, MittalB, NanjappaDP, et al.Identification of a novel TNFRSF11A gene variant in a rare case of familial osteopetrosis autosomal recessive type 7. Gene Rep, 2022; 29; doi: 10.1016/j.genrep.2022.101683
10.
BliznetzEA, TverskayaSM, ZinchenkoRA, et al.Genetic analysis of autosomal recessive osteopetrosis in chuvashiya: The unique splice site mutation in TCIRG1 gene spread by the founder effect. Eur J Hum Genet, 2009; 17(5):664–672; doi: 10.1038/ejhg.2008.234
11.
BoT, YanF, GuoJ, et al.Characterization of a relatively malignant form of osteopetrosis caused by a novel mutation in the PLEKHM1 gene. J Bone Miner Res, 2016; 31(11):1979–1987; doi: 10.1002/jbmr.2885
12.
BolampertiS, VillaI, RubinacciA. Bone remodeling: An operational process ensuring survival and bone mechanical competence. Bone Res, 2022; 10(1):48; doi: 10.1038/s41413-022-00219-8
13.
BollerslevJ, AndersenPE.Jr., Radiological, biochemical and hereditary evidence of two types of autosomal dominant osteopetrosis. Bone, 1988; 9(1):7–13; doi: 10.1016/8756-3282(88)90021-x
CareyHA, HildrethBE3rd, GeislerJA, et al.Enhancer variants reveal a conserved transcription factor network governed by PU.1 during osteoclast differentiation. Bone Res, 2018; 6:8; doi: 10.1038/s41413-018-0011-1
16.
CareyHA, HildrethBE, SamuvelDJ, et al.Eomes partners with PU.1 and MITF to regulate transcription factors critical for osteoclast differentiation. iScience, 2019; 11:238–245; doi: 10.1016/j.isci.2018.12.018DJ
17.
CaveyJR, RalstonSH, HockingLJ, et al.Loss of ubiquitin-binding associated with paget’s disease of bone p62 (SQSTM1) mutations. J Bone Miner Res, 2005; 20(4):619–624; doi: 10.1359/JBMR.041205LJ
18.
ChalhoubN, BenachenhouN, RajapurohitamV, et al.Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med, 2003; 9(4):399–406; doi: 10.1038/nm842
19.
ChenY, ZhouL, GuanX, et al.Case report: Gene mutations and clinical characteristics of four patients with osteopetrosis. Front Pediatr, 2023; 11:1096770; doi: 10.3389/fped.2023.1096770
20.
ChoiEB, AgidigbiTS, KangIS, et al.ERK inhibition increases RANKL-induced osteoclast differentiation in RAW 264.7 cells by stimulating AMPK activation and RANK expression and inhibiting anti-osteoclastogenic factor expression. Int J Mol Sci, 2022; 23(21):13512; doi: 10.3390/ijms232113512
21.
ChoiIA, UmemotoA, MizunoM, et al.Bone metabolism—an underappreciated player. NPJ Metab Health Dis, 2024; 2(1):12; doi: 10.1038/s44324-024-00010-9
22.
CleirenE, BénichouO, Van HulE, et al.Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet, 2001; 10(25):2861–2867; doi: 10.1093/hmg/10.25.2861
23.
DaiR, WuZ, ChuHY, et al.Cathepsin K: The action in and beyond bone. Front Cell Dev Biol, 2020; 8:433; doi: 10.3389/fcell.2020.00433
24.
Del FattoreA, PeruzziB, RucciN, et al.Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: Implications for diagnosis and treatment. J Med Genet, 2006; 43(4):315–325; doi: 10.1136/jmg.2005.036673
25.
Del FattoreA, FornariR, Van WesenbeeckL, et al.A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J Bone Miner Res, 2008; 23(3):380–391; doi: 10.1359/jbmr.071107
26.
DöffingerR, SmahiA, BessiaC, et al.X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet, 2001; 27(3):277–285; doi: 10.1038/85837
27.
DuanX, YangS, ZhangL, et al.V-ATPases and osteoclasts: Ambiguous future of V-ATPases inhibitors in osteoporosis. Theranostics, 2018; 8(19):5379–5399; doi: 10.7150/thno.28391
28.
ElahiE, ShafaghatiY, AsadiS, et al.Intragenic SNP haplotypes associated with 84dup18 mutation in TNFRSF11A in four FEO pedigrees suggest three independent origins for this mutation. J Bone Miner Metab, 2007; 25(3):159–164; doi: 10.1007/s00774-007-0748-x
29.
Eleveld-TrancikovaD, TriantisV, MoulinV, et al.The dendritic cell-derived protein DC-STAMP is highly conserved and localizes to the endoplasmic reticulum. J Leukoc Biol, 2005; 77(3):337–343; doi: 10.1189/jlb.0804441
30.
FrattiniA, PangrazioA, SusaniL, et al.Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res, 2003; 18(10):1740–1747; doi: 10.1359/jbmr.2003.18.10.1740
31.
GeethaT, WootenMW. Association of the atypical protein kinase C-interacting protein p62/ZIP with nerve growth factor receptor TrkA regulates receptor trafficking and Erk5 signaling. J Biol Chem, 2003; 278(7):4730–4739; doi: 10.1074/jbc.M208468200
32.
GelbBD, ShiGP, ChapmanHA, et al.Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science, 1996; 273(5279):1236–1238; doi: 10.1126/science.273.5279.1236
33.
GuerriniMM, SobacchiC, CassaniB, et al.Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet, 2008; 83(1):64–76; doi: 10.1016/j.ajhg.2008.06.015
34.
HadjidakisDJ, AndroulakisII. Bone remodeling. Ann N Y Acad Sci, 2006; 1092:385–396; doi: 10.1196/annals.1365.035
35.
HaldJD, Beck-NielsenS, GregersenPA, et al.Pycnodysostosis in children and adults. Bone, 2023; 169:116674; doi: 10.1016/j.bone.2023.116674
36.
HartgersFC, VissersJL, LoomanMW, et al.DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells. Eur J Immunol, 2000; 30(12):3585–3590; doi: 10.1002/1521-4141(200012)30:12<3585::AID-IMMU3585>3.0.CO;2-Y
37.
HaslamSI, Van HulW, Morales-PigaA, et al.Paget’s disease of bone: Evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res, 1998; 13(6):911–917; doi: 10.1359/jbmr.1998.13.6.911
38.
HaymanAR. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity, 2008; 41(3):218–223; doi: 10.1080/08916930701694667
39.
HelfrichMH. Osteoclast diseases. Microsc Res Tech, 2003; 61(6):514–532; doi: 10.1002/jemt.10375
40.
HockingLJ, LucasGJ, DaroszewskaA, et al.Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic paget’s disease. Hum Mol Genet, 2002; 11(22):2735–2739; doi: 10.1093/hmg/11.22.2735
41.
HodgeJM, CollierFM, PavlosNJ, et al.M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One, 2011; 6(6):e21462; doi: 10.1371/journal.pone.0021462
42.
HowaldtA, NampoothiriS, QuellLM, et al.Sclerosing bone dysplasias with hallmarks of dysosteosclerosis in four patients carrying mutations in SLC29A3 and TCIRG1. Bone, 2019; 120:495–503; doi: 10.1016/j.bone.2018.12.002
43.
HuPY, RothDE, SkaggsLA, et al.A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from arabic countries. Hum Mutat, 1992; 1(4):288–292; doi: 10.1002/humu.1380010404
44.
HuPY, LimEJ, CiccolellaJ, et al.Seven novel mutations in carbonic anhydrase II deficiency syndrome identified by SSCP and direct sequencing analysis. Hum Mutat, 1997; 9(5):383–387; doi: 10.1002/(SICI)1098-1004(1997)9:5<383::AID-HUMU1>3.0.CO;2-5
45.
HuangX, QiX, LiM, et al.A mutation in CTSK gene in an autosomal recessive pycnodysostosis family of chinese origin. Calcif Tissue Int, 2015; 96(5):373–378; doi: 10.1007/s00223-015-9963-y
46.
HughesAE, RalstonSH, MarkenJ, et al.Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet, 2000; 24(1):45–48; doi: 10.1038/71667
47.
HuynhJ, KwaMQ, CookAD, et al.CSF-1 receptor signalling from endosomes mediates the sustained activation of Erk1/2 and akt in macrophages. Cell Signal, 2012; 24(9):1753–1761; doi: 10.1016/j.cellsig.2012.04.022
48.
IshiyamaK, YashiroT, NakanoN, et al.Involvement of PU.1 in NFATc1 promoter function in osteoclast development. Allergol Int, 2015; 64(3):241–247; doi: 10.1016/j.alit.2015.01.006
49.
IzawaN, KurotakiD, NomuraS, et al.Cooperation of PU.1 with IRF8 and NFATc1 defines chromatin landscapes during RANKL-induced osteoclastogenesis. J Bone Miner Res, 2019; 34(6):1143–1154; doi: 10.1002/jbmr.3689
50.
JiangT, XiaT, QiaoF, et al.Role and regulation of transcription factors in osteoclastogenesis. Int J Mol Sci, 2023; 24(22):16175; doi: 10.3390/ijms242216175
51.
JiangA, ChenT, WeiN, et al.Identification of a novel mutation in the CLCN7 gene in pediatric osteopetrosis: Case report. Front Pediatr, 2025; 13:1549961; doi: 10.3389/fped.2025.1549961
52.
JimiE, KatagiriT. Critical roles of NF-κB signaling molecules in bone metabolism revealed by genetic mutations in osteopetrosis. Int J Mol Sci, 2022; 23(14):7995; doi: 10.3390/ijms23147995
53.
Johnson-PaisTL, WisdomJH, WeldonKS, et al.Three novel mutations in SQSTM1 identified in familial paget’s disease of bone. J Bone Miner Res, 2003; 18(10):1748–1753; doi: 10.1359/jbmr.2003.18.10.1748
54.
KimK, KimJH, LeeJ, et al.Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem, 2005; 280(42):35209–35216; doi: 10.1074/jbc.M505815200
55.
KimK, LeeSH, Ha KimJ, et al.NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol, 2008; 22(1):176–185; doi: 10.1210/me.2007-0237
56.
KimJH, KimN. Regulation of NFATc1 in osteoclast differentiation. J Bone Metab, 2014; 21(4):233–241; doi: 10.11005/jbm.2014.21.4.233
57.
KimJM, LinC, StavreZ, et al.Osteoblast-Osteoclast communication and bone homeostasis. Cells, 2020; 9(9):2073; doi: 10.3390/cells9092073
58.
KitauraH, MarahlehA, OhoriF, et al.Osteocyte-related cytokines regulate osteoclast formation and bone resorption. Int J Mol Sci, 2020; 21(14):5169; doi: 10.3390/ijms21145169
59.
KoçakG, GüzelBN, MıhçıE, et al.TCIRG1 and SNX10 gene mutations in the patients with autosomal recessive osteopetrosis. Gene, 2019; 702:83–88; doi: 10.1016/j.gene.2019.02.088
60.
KodamaJ, KaitoT. Osteoclast multinucleation: Review of current literature. Int J Mol Sci, 2020; 21(16):5685; doi: 10.3390/ijms21165685
61.
KohliSS, KohliVS. Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian J Endocrinol Metab, 2011; 15(3):175–181; doi: 10.4103/2230-8210.83401
62.
KornakU, KasperD, BöslMR, et al.Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell, 2001; 104(2):205–215; doi: 10.1016/s0092-8674(01)00206-9
63.
KwonOH, LeeCK, LeeYI, et al.The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. Biochem Biophys Res Commun, 2005; 335(2):437–446; doi: 10.1016/j.bbrc.2005.07.092
64.
LangePF, WartoschL, JentschTJ, et al.ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature, 2006; 440(7081):220–223; doi: 10.1038/nature04535
65.
LaurierE, AmiableN, GagnonE, et al.Effect of a rare genetic variant of TM7SF4 gene on osteoclasts of patients with paget’s disease of bone. BMC Med Genet, 2017; 18(1):133; doi: 10.1186/s12881-017-0495-3
66.
LaurinN, BrownJP, MorissetteJ, et al.Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet, 2002; 70(6):1582–1588; doi: 10.1086/340731
67.
LeeZH, KimHH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun, 2003; 305(2):211–214; doi: 10.1016/s0006-291x(03)00695-8
68.
LeisleL, LudwigCF, WagnerFA, et al.ClC-7 is a slowly voltage-gated 2Cl(-)/1H(+)-exchanger and requires Ostm1 for transport activity. Embo J, 2011; 30(11):2140–2152; doi: 10.1038/emboj.2011.137
69.
LiL, LvSS, WangC, et al.Novel CLCN7 mutations cause autosomal dominant osteopetrosis type II and intermediate autosomal recessive osteopetrosis. Mol Med Rep, 2019; 19(6):5030–5038; doi: 10.3892/mmr.2019.10123
70.
Lo IaconoN, PangrazioA, AbinunM, et al.RANKL cytokine: From pioneer of the osteoimmunology era to cure for a rare disease. Clin Dev Immunol, 2013; 2013:412768; doi: 10.1155/2013/412768
LuchinA, PurdomG, MurphyK, et al.The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts. J Bone Miner Res, 2000; 15(3):451–460; doi: 10.1359/jbmr.2000.15.3.451
73.
MaoL, WangL, XuJ, et al.The role of integrin family in bone metabolism and tumor bone metastasis. Cell Death Discov, 2023; 9(1):119; doi: 10.1038/s41420-023-01417-x
74.
MatsumotoM, KogawaM, WadaS, et al.Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem, 2004; 279(44):45969–45979; doi: 10.1074/jbc.M408795200
75.
McGillGG, HorstmannM, WidlundHR, et al.Bcl2 regulation by the melanocyte master regulator mitf modulates lineage survival and melanoma cell viability. Cell, 2002; 109(6):707–718; doi: 10.1016/s0092-8674(02)00762-6
76.
MégarbanéA, PangrazioA, VillaA, et al.Homozygous stop mutation in the SNX10 gene in a consanguineous iraqi boy with osteopetrosis and corpus callosum hypoplasia. Eur J Med Genet, 2013; 56(1):32–35; doi: 10.1016/j.ejmg.2012.10.010
77.
MenaaC, KuriharaN, RoodmanGD. CFU-GM-derived cells form osteoclasts at a very high efficiency. Biochem Biophys Res Commun, 2000; 267(3):943–946; doi: 10.1006/bbrc.1999.2042
78.
MiyamotoT, OhnedaO, AraiF, et al.Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood, 2001; 98(8):2544–2554; doi: 10.1182/blood.v98.8.2544
79.
MizukamiJ, TakaesuG, AkatsukaH, et al.Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol, 2002; 22(4):992–1000; doi: 10.1128/MCB.22.4.992-1000.2002
80.
Mossadegh-KellerN, SarrazinS, KandallaPK, et al.M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. Nature, 2013; 497(7448):239–243; doi: 10.1038/nature12026
81.
MunSH, ParkPSU, Park-MinKH. The M-CSF receptor in osteoclasts and beyond. Exp Mol Med, 2020; 52(8):1239–1254; doi: 10.1038/s12276-020-0484-z
82.
NadyrshinaDD, KhusainovaRI. Clinical, genetic aspects and molecular pathogenesis of osteopetrosis. Vavilovskii Zhurnal Genet Selektsii, 2023; 27(4):383–392; doi: 10.18699/VJGB-23-46
83.
NaeemM, SheikhS, AhmadW. A mutation in CTSK gene in an autosomal recessive pycnodysostosis family of Pakistani origin. BMC Med Genet, 2009; 10:76; doi: 10.1186/1471-2350-10-76
84.
NakagawaN, KinosakiM, YamaguchiK, et al.RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun, 1998; 253(2):395–400; doi: 10.1006/bbrc.1998.9788
85.
NakaiH, ByersMG, VentaPJ, et al.The gene for human carbonic anhydrase II (CA2) is located at chromosome 8q22. Cytogenet Cell Genet, 1987; 44(4):234–235; doi: 10.1159/000132378
86.
NakashimaT, TakayanagiH. New regulation mechanisms of osteoclast differentiation. Ann N Y Acad Sci, 2011; 1240:E13–E18; doi: 10.1111/j.1749-6632.2011.06373.x
87.
NedevaIR, VitaleM, ElsonA, et al.Role of OSCAR signaling in osteoclastogenesis and bone disease. Front Cell Dev Biol, 2021; 9:641162; doi: 10.3389/fcell.2021.641162
88.
OmataY, TachibanaH, AizakiY, et al.Essentiality of Nfatc1 short isoform in osteoclast differentiation and its self-regulation. Sci Rep, 2023; 13(1):18797; doi: 10.1038/s41598-023-45909-3
89.
OsterbergPH, WallaceRG, AdamsDA, et al.Familial expansile osteolysis. A new dysplasia. J Bone Joint Surg Br, 1988; 70(2):255–260; doi: 10.1302/0301-620X.70B2.3346299
90.
OttCE, FischerB, SchröterP, et al.Severe neuronopathic autosomal recessive osteopetrosis due to homozygous deletions affecting OSTM1. Bone, 2013; 55(2):292–297; doi: 10.1016/j.bone.2013.04.007
91.
PalenzuelaL, Vives-BauzaC, Fernández-CadenasI, et al.Familial expansile osteolysis in a large spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. J Med Genet, 2002; 39(10):E67; doi: 10.1136/jmg.39.10.e67
92.
PangM, Rodríguez-GonzalezM, HernandezM, et al.AP-1 and mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors. J Cell Biochem, 2019; 120(8):12382–12392; doi: 10.1002/jcb.28504
93.
PangrazioA, PolianiPL, MegarbaneA, et al.Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner Res, 2006; 21(7):1098–1105; doi: 10.1359/jbmr.060403
94.
PangrazioA, FasthA, SbardellatiA, et al.SNX10 mutations define a subgroup of human autosomal recessive osteopetrosis with variable clinical severity. J Bone Miner Res, 2013; 28(5):1041–1049; doi: 10.1002/jbmr.1849
95.
ParfittAM. Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem, 1994; 55(3):273–286; doi: 10.1002/jcb.240550303
96.
PennaS, CapoV, PalaganoE, et al.One disease, many genes: Implications for the treatment of osteopetroses. Front Endocrinol (Lausanne), 2019; 10:85; doi: 10.3389/fendo.2019.00085
RalstonSH, LayfieldR. Pathogenesis of Paget disease of bone. Calcif Tissue Int, 2012; 91(2):97–113; doi: 10.1007/s00223-012-9599-0
99.
QinA, ChengTS, PavlosNJ, et al.V-ATPases in osteoclasts: Structure, function and potential inhibitors of bone resorption. Int J Biochem Cell Biol, 2012; 44(9):1422–1435; doi: 10.1016/j.biocel.2012.05.014
100.
QuarelloP, ForniM, BarberisL, et al.Severe malignant osteopetrosis caused by a GL gene mutation. J Bone Miner Res, 2004; 19(7):1194–1199; doi: 10.1359/JBMR.040407
101.
RamírezA, FaupelJ, GoebelI, et al.Identification of a novel mutation in the coding region of the grey-lethal gene OSTM1 in human malignant infantile osteopetrosis. Hum Mutat, 2004; 23(5):471–476; doi: 10.1002/humu.20028
102.
RothDE, VentaPJ, TashianRE, et al.Molecular basis of human carbonic anhydrase II deficiency. Proc Natl Acad Sci U S A, 1992; 89(5):1804–1808; doi: 10.1073/pnas.89.5.1804
103.
RousselleAV, HeymannD. Osteoclastic acidification pathways during bone resorption. Bone, 2002; 30(4):533–540; doi: 10.1016/s8756-3282(02)00672-5
104.
SaitH, SrivastavaP, GuptaN, et al.Phenotypic and genotypic spectrum of CTSK variants in a cohort of twenty-five indian patients with pycnodysostosis. Eur J Med Genet, 2021; 64(7):104235; doi: 10.1016/j.ejmg.2021.104235
105.
SarrazinS, Mossadegh-KellerN, FukaoT, et al.MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells. Cell, 2009; 138(2):300–313; doi: 10.1016/j.cell.2009.04.057
106.
SarrazinS, SiewekeM. Integration of cytokine and transcription factor signals in hematopoietic stem cell commitment. Semin Immunol, 2011; 23(5):326–334; doi: 10.1016/j.smim.2011.08.011
107.
SawataniY, MiyamotoT, NagaiS, et al.The role of DC-STAMP in maintenance of immune tolerance through regulation of dendritic cell function. Int Immunol, 2008; 20(10):1259–1268; doi: 10.1093/intimm/dxn082
108.
SchindelerA, McDonaldMM, BokkoP, et al.Bone remodeling during fracture repair: The cellular picture. Semin Cell Dev Biol, 2008; 19(5):459–466; doi: 10.1016/j.semcdb.2008.07.004
109.
Segovia-SilvestreT, Neutzsky-WulffAV, SorensenMG, et al.Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet, 2009; 124(6):561–577; doi: 10.1007/s00439-008-0583-8
110.
SharmaSM, BroniszA, HuR, et al.MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem, 2007; 282(21):15921–15929; doi: 10.1074/jbc.M609723200
111.
SimonetWS, LaceyDL, DunstanCR, et al.Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 1997; 89(2):309–319; doi: 10.1016/s0092-8674(00)80209-3
112.
SinghH, DeKoterRP, WalshJC. PU.1, a shared transcriptional regulator of lymphoid and myeloid cell fates. Cold Spring Harb Symp Quant Biol, 1999; 64:13–20; doi: 10.1101/sqb.1999.64.13
113.
SobacchiC, FrattiniA, GuerriniMM, et al.Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet, 2007; 39(8):960–962; doi: 10.1038/ng2076
114.
SobacchiC, SchulzA, CoxonFP, et al.Osteopetrosis: Genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol, 2013; 9(9):522–536; doi: 10.1038/nrendo.2013.137
115.
SodaH, YukizaneS, YoshidaI, et al.A point mutation in exon 3 (his 107–>tyr) in two unrelated japanese patients with carbonic anhydrase II deficiency with Central nervous system involvement. Hum Genet, 1996; 97(4):435–437; doi: 10.1007/BF02267062
116.
SongXL, PengLY, WangDW, et al.Autosomal dominant osteopetrosis type II resulting from a de novo mutation in the CLCN7 gene: A case report. World J Clin Cases, 2022; 10(20):6936–6943; doi: 10.12998/wjcc.v10.i20.6936
117.
StattinEL, HenningP, KlarJ, et al.SNX10 gene mutation leading to osteopetrosis with dysfunctional osteoclasts. Sci Rep, 2017; 7(1):3012; doi: 10.1038/s41598-017-02533-2
118.
StenbeckG. Formation and function of the ruffled border in osteoclasts. Semin Cell Dev Biol, 2002; 13(4):285–292; doi: 10.1016/s1084952102000587
119.
SunY, LiJ, XieX, et al.Macrophage-osteoclast associations: Origin, polarization, and subgroups. Front Immunol, 2021; 12:778078; doi: 10.3389/fimmu.2021.778078
120.
TagohH, HimesR, ClarkeD, et al.Transcription factor complex formation and chromatin fine structure alterations at the murine c-fms (CSF-1 receptor) locus during maturation of myeloid precursor cells. Genes Dev, 2002; 16(13):1721–1737; doi: 10.1101/gad.222002
121.
TakayanagiH, KimS, KogaT, et al.Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell, 2002; 3(6):889–901; doi: 10.1016/s1534-5807(02)00369-6
122.
TakegaharaN, KimH, MizunoH, et al.Involvement of receptor activator of nuclear factor-κB ligand (RANKL)-induced incomplete cytokinesis in the polyploidization of osteoclasts. J Biol Chem, 2016; 291(7):3439–3454; doi: 10.1074/jbc.M115.677427
123.
TakegaharaN, KimH, ChoiY. Unraveling the intricacies of osteoclast differentiation and maturation: Insight into novel therapeutic strategies for bone-destructive diseases. Exp Mol Med, 2024; 56(2):264–272; doi: 10.1038/s12276-024-01157-7
124.
TakitoJ, InoueS, NakamuraM. The sealing zone in osteoclasts: A self-organized structure on the bone. Int J Mol Sci, 2018; 19(4):984; doi: 10.3390/ijms19040984
125.
TeitelbaumSL. Bone resorption by osteoclasts. Science, 2000; 289(5484):1504–1508; doi: 10.1126/science.289.5484.1504
126.
TeitelbaumSL, RossFP. Genetic regulation of osteoclast development and function. Nat Rev Genet, 2003; 4(8):638–649; doi: 10.1038/nrg1122
127.
TezukaK, TezukaY, MaejimaA, et al.Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem, 1994; 269(2):1106–1109; doi: 10.1016/S0021-9258(17)42227-7
TondraviMM, McKercherSR, AndersonK, et al.Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature, 1997; 386(6620):81–84; doi: 10.1038/386081a0
130.
VacherJ. OSTM1 pleiotropic roles from osteopetrosis to neurodegeneration. Bone, 2022; 163:116505; doi: 10.1016/j.bone.2022.116505
131.
Van HulE, GramJ, BollerslevJ, et al.Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. J Bone Miner Res, 2002; 17(6):1111–1117; doi: 10.1359/jbmr.2002.17.6.1111
132.
Van WesenbeeckL, OdgrenPR, CoxonFP, et al.Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest, 2007; 117(4):919–930; doi: 10.1172/JCI30328
133.
WalshMC, KimN, KadonoY, et al.Osteoimmunology: Interplay between the immune system and bone metabolism. Annu Rev Immunol, 2006; 24:33–63; doi: 10.1146/annurev.immunol.24.021605.090646
134.
WangL, YouX, ZhangL, et al.Mechanical regulation of bone remodeling. Bone Res, 2022; 10(1):16; doi: 10.1038/s41413-022-00190-4
135.
WeilbaecherKN, MotyckovaG, HuberWE, et al.Linkage of M-CSF signaling to mitf, TFE3, and the osteoclast defect in mitf (mi/mi) mice. Mol Cell, 2001; 8(4):749–758; doi: 10.1016/s1097-2765(01)00360-4
136.
WeivodaMM, ChewCK, MonroeDG, et al.Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat Commun, 2020; 11(1):87; doi: 10.1038/s41467-019-14003-6
137.
WisitrasameewongW, KajiyaM, MovilaA, et al.DC-STAMP is an osteoclast fusogen engaged in periodontal bone resorption. J Dent Res, 2017; 96(6):685–693; doi: 10.1177/0022034517690490
138.
WuJ, GlimcherLH, AliprantisAO. HCO3-/Cl- anion exchanger SLC4A2 is required for proper osteoclast differentiation and function. Proc Natl Acad Sci U S A, 2008; 105(44):16934–16939; doi: 10.1073/pnas.0808763105
139.
WuCC, EconsMJ, DiMeglioLA, et al.Diagnosis and management of osteopetrosis: Consensus guidelines from the osteopetrosis working group. J Clin Endocrinol Metab, 2017; 102(9):3111–3123; doi: 10.1210/jc.2017-01127
140.
XueY, CaiT, ShiS, et al.Clinical and animal research findings in pycnodysostosis and gene mutations of cathepsin K from 1996 to 2011. Orphanet J Rare Dis, 2011; 6:20; doi: 10.1186/1750-1172-6-20
141.
XueJY, GrigelionieneG, WangZ, et al.SLC4A2 deficiency causes a new type of osteopetrosis. J Bone Miner Res, 2022; 37(2):226–235; doi: 10.1002/jbmr.4462
142.
YagiM, MiyamotoT, SawataniY, et al.DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med, 2005; 202(3):345–351; doi: 10.1084/jem.20050645
143.
YangM, BirnbaumMJ, MacKayCA, et al.Osteoclast stimulatory transmembrane protein (OC-STAMP), a novel protein induced by RANKL that promotes osteoclast differentiation. J Cell Physiol, 2008; 215(2):497–505; doi: 10.1002/jcp.21331
144.
ZengB, LiR, HuY, et al.A novel mutation and a known mutation in the CLCN7 gene associated with relatively stable infantile malignant osteopetrosis in a Chinese patient. Gene, 2016; 576(1 Pt 1):176–181; doi: 10.1016/j.gene.2015.10.021
145.
ZhangDE, HetheringtonCJ, ChenHM, et al.The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. Mol Cell Biol, 1994; 14(1):373–381; doi: 10.1128/mcb.14.1.373-381.1994
146.
ZhangXY, HeJW, FuWZ, et al.Novel mutations of TCIRG1 cause a malignant and mild phenotype of autosomal recessive osteopetrosis (ARO) in four chinese families. Acta Pharmacol Sin, 2017; 38(11):1456–1465; doi: 10.1038/aps.2017.108
147.
ZhaoW, QianJ, LiJ, et al.From death to birth: How osteocyte death promotes osteoclast formation. Front Immunol, 2025; 16:1551542; doi: 10.3389/fimmu.2025.1551542
148.
ZhuL, TangY, LiXY, et al.Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. Sci Transl Med, 2020; 12(529):eaaw6143; doi: 10.1126/scitranslmed.aaw6143
149.
ZirngiblRA, WangA, YaoY, et al.Novel c.G630A TCIRG1 mutation causes aberrant splicing resulting in an unusually mild form of autosomal recessive osteopetrosis. J Cell Biochem, 2019; 120(10):17180–17193; doi: 10.1002/jcb.28979
150.
ZouN, LiuR, LiC. Cathepsin K+ non-osteoclast cells in the skeletal system: Function, models, identity, and therapeutic implications. Front Cell Dev Biol, 2022; 10:818462; doi: 10.3389/fcell.2022.818462
151.
ŽivkovićJM, NajmanSJ, VukelićMĐ, et al.Osteogenic effect of inflammatory macrophages loaded onto mineral bone substitute in subcutaneous implants. Arch Biol Sci (Beogr), 2015; 67(1):173–186; doi: 10.2298/ABS140915020Z
152.
ŽivkovićJM, StojanovićST, Vukelić-NikolićMĐ, et al.Macrophages’ contribution to ectopic osteogenesis in combination with blood clot and bone substitute: Possibility for application in bone regeneration strategies. Int Orthop, 2021; 45(4):1087–1095; doi: 10.1007/s00264-020-04826-0
